Community pharmacies in England are being handed a bigger clinical role from autumn 2026, with independent prescribing being added as an extension of Pharmacy First. For pharmacies across the country, the change brings new conditions they can treat, a dedicated funding stream, and a decision about whether it is worth signing up.
What is changing
Pharmacy First already lets pharmacies supply treatment for seven common conditions without a GP referral. From the planned October 2026 start, pharmacies that employ an independent prescriber will be able to add five more: migraine, rhinitis, adult ear infections, acne and scabies, according to NHS England plans reported by the Pharmaceutical Journal. A further batch of conditions, including bacterial and allergic conjunctivitis, oral thrush, skin infections and respiratory tract infections, has been proposed but still needs sign-off from a clinical reference group before it is confirmed.
The prescribing service sits alongside the existing Pharmacy Contraception Service, and the aim is the same: let people get treated at their local chemist, whether that is in Westminster or a smaller high street elsewhere, instead of waiting for a GP appointment.
The funding on offer
Pharmacies that take part are being offered a one-off £500 setup payment plus a monthly infrastructure payment of £525. That sits on top of the wider 2026/27 contract settlement, which makes £3.636bn available to the community pharmacy sector and lifts the single activity fee from £1.46 to £1.52, backdated to May 2026.
Pharmacy First has also moved into the core contract framework, meaning any underspend now stays within the sector rather than reverting to NHS England centrally. That change matters: £5.6m went unspent and unreinvested in 2025/26, even as pharmacies delivered more than 3.3 million Pharmacy First consultations between March 2025 and February 2026.
Why it is not a straightforward yes for every pharmacy
Community Pharmacy England, which represents contractors, has struck a cautious note. Its chief executive has pointed out that only around one in five pharmacies currently employs an independent prescriber, and has urged contractors to think carefully before committing, given lingering doubts about whether the funding will cover the extra workload the new pathways bring. For a pharmacy without an independent prescriber already on the team, taking part means recruiting or training one first, not simply opting in.
What it means for customers
For patients, the practical effect depends entirely on which pharmacies sign up. Where a pharmacy does have an independent prescriber, the five new conditions mean a prescription without a GP appointment, and pharmacists get more flexibility to substitute an equivalent item when a prescribed product is affected by a supply shortage. Anyone searching for a pharmacy near them that is taking part will still need to check with individual branches, since uptake so far has been patchy. The Pharmaceutical Journal has more detail on the proposed pathways and timetable.
